Definition and Scope: mRNA vaccines for infectious diseases are a type of vaccine that uses messenger RNA to instruct cells in the body to produce a protein that triggers an immune response. This immune response helps the body recognize and fight off the infectious agent, providing protection against specific diseases. mRNA vaccines have gained significant attention and popularity in recent years due to their ability to be developed and manufactured quickly, as demonstrated by the rapid development of mRNA vaccines for COVID-19. These vaccines are considered a groundbreaking technology in the field of immunization, offering potential advantages such as scalability, flexibility, and the absence of live pathogens, making them a promising tool in the fight against infectious diseases. The market for mRNA vaccines for infectious diseases is experiencing a significant upward trend, driven by several factors. One key driver is the growing global demand for effective and innovative vaccines to combat infectious diseases, particularly in the wake of the COVID-19 pandemic. The success of mRNA vaccines in providing a rapid response to the pandemic has highlighted their potential and paved the way for further research and development in this area. Additionally, advancements in mRNA technology, increased funding for vaccine research, and collaborations between pharmaceutical companies and research institutions are fueling the expansion of the market. As a result, more companies are investing in the development of mRNA vaccines for a wide range of infectious diseases, leading to a competitive and dynamic market landscape. At the same time, market drivers such as the increasing prevalence of infectious diseases, the need for more effective and targeted vaccines, and the growing awareness of the importance of vaccination in disease prevention are further propelling the growth of the mRNA vaccine market. Governments and healthcare organizations are also recognizing the potential of mRNA vaccines in addressing public health challenges and are actively supporting research and deployment efforts. Moreover, the ongoing technological advancements in mRNA vaccine production, distribution, and storage are overcoming previous limitations and expanding the market's reach. Overall, the market for mRNA vaccines for infectious diseases is poised for continued growth and innovation, driven by a combination of scientific progress, market demand, and industry collaboration. The global mRNA Vaccines for Infectious Diseases market size was estimated at USD 31826.25 million in 2024, exhibiting a CAGR of 2.50% during the forecast period. This report offers a comprehensive analysis of the global mRNA Vaccines for Infectious Diseases market, examining all key dimensions. It provides both a macro-level overview and micro-level market details, including market size, trends, competitive landscape, niche segments, growth drivers, and key challenges. Report Framework and Key Highlights: Market Dynamics: Identification of major market drivers, restraints, opportunities, and challenges. Trend Analysis: Examination of ongoing and emerging trends impacting the market. Competitive Landscape: Detailed profiles and market positioning of major players, including market share, operational status, product offerings, and strategic developments. Strategic Analysis Tools: SWOT Analysis, Porter’s Five Forces Analysis, PEST Analysis, Value Chain Analysis Market Segmentation: By type, application, region, and end-user industry. Forecasting and Growth Projections: In-depth revenue forecasts and CAGR analysis through 2033. This report equips readers with critical insights to navigate competitive dynamics and develop effective strategies. Whether assessing a new market entry or refining existing strategies, the report serves as a valuable tool for: Industry players Investors Researchers Consultants Business strategists And all stakeholders with an interest or investment in the mRNA Vaccines for Infectious Diseases market. Global mRNA Vaccines for Infectious Diseases Market: Segmentation Analysis and Strategic Insights This section of the report provides an in-depth segmentation analysis of the global mRNA Vaccines for Infectious Diseases market. The market is segmented based on region (country), manufacturer, product type, and application. Segmentation enables a more precise understanding of market dynamics and facilitates targeted strategies across product development, marketing, and sales. By breaking the market into meaningful subsets, stakeholders can better tailor their offerings to the specific needs of each segment—enhancing competitiveness and improving return on investment. Global mRNA Vaccines for Infectious Diseases Market: Market Segmentation Analysis The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments. Key Companies Profiled Moderna Therapeutics CureVac Translate Bio BioNTech Sangamo Therapeutics Argos Therapeutics In-Cell-Art eTheRNA Ethris Tiba Biotechnology Market Segmentation by Type Infectious Disease Vaccines Cancer Vaccines Market Segmentation by Application Infectious Disease Cancer Geographic Segmentation North America: United States, Canada, Mexico Europe: Germany, France, Italy, U.K., Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium, Russia. Asia-Pacific: China, Japan, South Korea, India, Australia, Indonesia, Malaysia, Philippines, Singapore, Thailand South America: Brazil, Argentina, Colombia. Middle East and Africa (MEA): Saudi Arabia, United Arab Emirates, Egypt, Nigeria, South Africa, Rest of MEA Report Framework and Chapter Summary Chapter 1: Report Scope and Market Definition This chapter outlines the statistical boundaries and scope of the report. It defines the segmentation standards used throughout the study, including criteria for dividing the market by region, product type, application, and other relevant dimensions. It establishes the foundational definitions and classifications that guide the rest of the analysis. Chapter 2: Executive Summary This chapter presents a concise summary of the market’s current status and future outlook across different segments—by geography, product type, and application. It includes key metrics such as market size, growth trends, and development potential for each segment. The chapter offers a high-level overview of the mRNA Vaccines for Infectious Diseases Market, highlighting its evolution over the short, medium, and long term. Chapter 3: Market Dynamics and Policy Environment This chapter explores the latest developments in the market, identifying key growth drivers, restraints, challenges, and risks faced by industry participants. It also includes an analysis of the policy and regulatory landscape affecting the market, providing insight into how external factors may shape future performance. Chapter 4: Competitive Landscape This chapter provides a detailed assessment of the market's competitive environment. It covers market share, production capacity, output, pricing trends, and strategic developments such as mergers, acquisitions, and expansion plans of leading players. This analysis offers a comprehensive view of the positioning and performance of top competitors. Chapters 5–10: Regional Market Analysis These chapters offer in-depth, quantitative evaluations of market size and growth potential across major regions and countries. Each chapter assesses regional consumption patterns, market dynamics, development prospects, and available capacity. The analysis helps readers understand geographical differences and opportunities in global markets. Chapter 11: Market Segmentation by Product Type This chapter examines the market based on product type, analyzing the size, growth trends, and potential of each segment. It helps stakeholders identify underexplored or high-potential product categories—often referred to as “blue ocean” opportunities. Chapter 12: Market Segmentation by Application This chapter analyzes the market based on application fields, providing insights into the scale and future development of each application segment. It supports readers in identifying high-growth areas across downstream markets. Chapter 13: Company Profiles This chapter presents comprehensive profiles of leading companies operating in the market. For each company, it details sales revenue, volume, pricing, gross profit margin, market share, product offerings, and recent strategic developments. This section offers valuable insight into corporate performance and strategy. Chapter 14: Industry Chain and Value Chain Analysis This chapter explores the full industry chain, from upstream raw material suppliers to downstream application sectors. It includes a value chain analysis that highlights the interconnections and dependencies across various parts of the ecosystem. Chapter 15: Key Findings and Conclusions The final chapter summarizes the main takeaways from the report, presenting the core conclusions, strategic recommendations, and implications for stakeholders. It encapsulates the insights drawn from all previous chapters. Table of Contents 1 Introduction to Research & Analysis Reports 1.1 mRNA Vaccines for Infectious Diseases Market Definition 1.2 mRNA Vaccines for Infectious Diseases Market Segments 1.2.1 Segment by Type 1.2.2 Segment by Application 2 Executive Summary 2.1 Global mRNA Vaccines for Infectious Diseases Market Size 2.2 Market Segmentation – by Type 2.3 Market Segmentation – by Application 2.4 Market Segmentation – by Geography 3 Key Market Trends, Opportunity, Drivers and Restraints 3.1 Key Takeway 3.2 Market Opportunities & Trends 3.3 Market Drivers 3.4 Market Restraints 3.5 Market Major Factor Assessment 4 Global mRNA Vaccines for Infectious Diseases Market Competitive Landscape 4.1 Global mRNA Vaccines for Infectious Diseases Sales by Manufacturers (2020-2025) 4.2 Global mRNA Vaccines for Infectious Diseases Revenue Market Share by Manufacturers (2020-2025) 4.3 mRNA Vaccines for Infectious Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 4.4 New Entrant and Capacity Expansion Plans 4.5 Mergers & Acquisitions 5 Global mRNA Vaccines for Infectious Diseases Market by Region 5.1 Global mRNA Vaccines for Infectious Diseases Market Size by Region 5.1.1 Global mRNA Vaccines for Infectious Diseases Market Size by Region 5.1.2 Global mRNA Vaccines for Infectious Diseases Market Size Market Share by Region 5.2 Global mRNA Vaccines for Infectious Diseases Sales by Region 5.2.1 Global mRNA Vaccines for Infectious Diseases Sales by Region 5.2.2 Global mRNA Vaccines for Infectious Diseases Sales Market Share by Region 6 North America Market Overview 6.1 North America mRNA Vaccines for Infectious Diseases Market Size by Country 6.1.1 USA Market Overview 6.1.2 Canada Market Overview 6.1.3 Mexico Market Overview 6.2 North America mRNA Vaccines for Infectious Diseases Market Size by Type 6.3 North America mRNA Vaccines for Infectious Diseases Market Size by Application 6.4 Top Players in North America mRNA Vaccines for Infectious Diseases Market 7 Europe Market Overview 7.1 Europe mRNA Vaccines for Infectious Diseases Market Size by Country 7.1.1 Germany Market Overview 7.1.2 France Market Overview 7.1.3 U.K. Market Overview 7.1.4 Italy Market Overview 7.1.5 Spain Market Overview 7.1.6 Sweden Market Overview 7.1.7 Denmark Market Overview 7.1.8 Netherlands Market Overview 7.1.9 Switzerland Market Overview 7.1.10 Belgium Market Overview 7.1.11 Russia Market Overview 7.2 Europe mRNA Vaccines for Infectious Diseases Market Size by Type 7.3 Europe mRNA Vaccines for Infectious Diseases Market Size by Application 7.4 Top Players in Europe mRNA Vaccines for Infectious Diseases Market 8 Asia-Pacific Market Overview 8.1 Asia-Pacific mRNA Vaccines for Infectious Diseases Market Size by Country 8.1.1 China Market Overview 8.1.2 Japan Market Overview 8.1.3 South Korea Market Overview 8.1.4 India Market Overview 8.1.5 Australia Market Overview 8.1.6 Indonesia Market Overview 8.1.7 Malaysia Market Overview 8.1.8 Philippines Market Overview 8.1.9 Singapore Market Overview 8.1.10 Thailand Market Overview 8.1.11 Rest of APAC Market Overview 8.2 Asia-Pacific mRNA Vaccines for Infectious Diseases Market Size by Type 8.3 Asia-Pacific mRNA Vaccines for Infectious Diseases Market Size by Application 8.4 Top Players in Asia-Pacific mRNA Vaccines for Infectious Diseases Market 9 South America Market Overview 9.1 South America mRNA Vaccines for Infectious Diseases Market Size by Country 9.1.1 Brazil Market Overview 9.1.2 Argentina Market Overview 9.1.3 Columbia Market Overview 9.2 South America mRNA Vaccines for Infectious Diseases Market Size by Type 9.3 South America mRNA Vaccines for Infectious Diseases Market Size by Application 9.4 Top Players in South America mRNA Vaccines for Infectious Diseases Market 10 Middle East and Africa Market Overview 10.1 Middle East and Africa mRNA Vaccines for Infectious Diseases Market Size by Country 10.1.1 Saudi Arabia Market Overview 10.1.2 UAE Market Overview 10.1.3 Egypt Market Overview 10.1.4 Nigeria Market Overview 10.1.5 South Africa Market Overview 10.2 Middle East and Africa mRNA Vaccines for Infectious Diseases Market Size by Type 10.3 Middle East and Africa mRNA Vaccines for Infectious Diseases Market Size by Application 10.4 Top Players in Middle East and Africa mRNA Vaccines for Infectious Diseases Market 11 mRNA Vaccines for Infectious Diseases Market Segmentation by Type 11.1 Evaluation Matrix of Segment Market Development Potential (Type) 11.2 Global mRNA Vaccines for Infectious Diseases Sales Market Share by Type (2020-2033) 11.3 Global mRNA Vaccines for Infectious Diseases Market Size Market Share by Type (2020-2033) 11.4 Global mRNA Vaccines for Infectious Diseases Price by Type (2020-2033) 12 mRNA Vaccines for Infectious Diseases Market Segmentation by Application 12.1 Evaluation Matrix of Segment Market Development Potential (Application) 12.2 Global mRNA Vaccines for Infectious Diseases Market Sales by Application (2020-2033) 12.3 Global mRNA Vaccines for Infectious Diseases Market Size (M USD) by Application (2020-2033) 12.4 Global mRNA Vaccines for Infectious Diseases Sales Growth Rate by Application (2020-2033) 13 Company Profiles 13.1 Moderna Therapeutics 13.1.1 Moderna Therapeutics Company Overview 13.1.2 Moderna Therapeutics Business Overview 13.1.3 Moderna Therapeutics mRNA Vaccines for Infectious Diseases Major Product Offerings 13.1.4 Moderna Therapeutics mRNA Vaccines for Infectious Diseases Sales and Revenue frommRNA Vaccines for Infectious Diseases (2020-2025) 13.1.5 Key News 13.2 CureVac 13.2.1 CureVac Company Overview 13.2.2 CureVac Business Overview 13.2.3 CureVac mRNA Vaccines for Infectious Diseases Major Product Offerings 13.2.4 CureVac mRNA Vaccines for Infectious Diseases Sales and Revenue frommRNA Vaccines for Infectious Diseases (2020-2025) 13.2.5 Key News 13.3 Translate Bio 13.3.1 Translate Bio Company Overview 13.3.2 Translate Bio Business Overview 13.3.3 Translate Bio mRNA Vaccines for Infectious Diseases Major Product Offerings 13.3.4 Translate Bio mRNA Vaccines for Infectious Diseases Sales and Revenue frommRNA Vaccines for Infectious Diseases (2020-2025) 13.3.5 Key News 13.4 BioNTech 13.4.1 BioNTech Company Overview 13.4.2 BioNTech Business Overview 13.4.3 BioNTech mRNA Vaccines for Infectious Diseases Major Product Offerings 13.4.4 BioNTech mRNA Vaccines for Infectious Diseases Sales and Revenue frommRNA Vaccines for Infectious Diseases (2020-2025) 13.4.5 Key News 13.5 Sangamo Therapeutics 13.5.1 Sangamo Therapeutics Company Overview 13.5.2 Sangamo Therapeutics Business Overview 13.5.3 Sangamo Therapeutics mRNA Vaccines for Infectious Diseases Major Product Offerings 13.5.4 Sangamo Therapeutics mRNA Vaccines for Infectious Diseases Sales and Revenue frommRNA Vaccines for Infectious Diseases (2020-2025) 13.5.5 Key News 13.6 Argos Therapeutics 13.6.1 Argos Therapeutics Company Overview 13.6.2 Argos Therapeutics Business Overview 13.6.3 Argos Therapeutics mRNA Vaccines for Infectious Diseases Major Product Offerings 13.6.4 Argos Therapeutics mRNA Vaccines for Infectious Diseases Sales and Revenue frommRNA Vaccines for Infectious Diseases (2020-2025) 13.6.5 Key News 13.7 In-Cell-Art 13.7.1 In-Cell-Art Company Overview 13.7.2 In-Cell-Art Business Overview 13.7.3 In-Cell-Art mRNA Vaccines for Infectious Diseases Major Product Offerings 13.7.4 In-Cell-Art mRNA Vaccines for Infectious Diseases Sales and Revenue frommRNA Vaccines for Infectious Diseases (2020-2025) 13.7.5 Key News 13.8 eTheRNA 13.8.1 eTheRNA Company Overview 13.8.2 eTheRNA Business Overview 13.8.3 eTheRNA mRNA Vaccines for Infectious Diseases Major Product Offerings 13.8.4 eTheRNA mRNA Vaccines for Infectious Diseases Sales and Revenue frommRNA Vaccines for Infectious Diseases (2020-2025) 13.8.5 Key News 13.9 Ethris 13.9.1 Ethris Company Overview 13.9.2 Ethris Business Overview 13.9.3 Ethris mRNA Vaccines for Infectious Diseases Major Product Offerings 13.9.4 Ethris mRNA Vaccines for Infectious Diseases Sales and Revenue frommRNA Vaccines for Infectious Diseases (2020-2025) 13.9.5 Key News 13.10 Tiba Biotechnology 13.10.1 Tiba Biotechnology Company Overview 13.10.2 Tiba Biotechnology Business Overview 13.10.3 Tiba Biotechnology mRNA Vaccines for Infectious Diseases Major Product Offerings 13.10.4 Tiba Biotechnology mRNA Vaccines for Infectious Diseases Sales and Revenue frommRNA Vaccines for Infectious Diseases (2020-2025) 13.10.5 Key News 14 Key Market Trends, Opportunity, Drivers and Restraints 14.1 Key Takeway 14.2 Market Opportunities & Trends 14.3 Market Drivers 14.4 Market Restraints 14.5 Market Major Factor Assessment 14.6 Porter's Five Forces Analysis of mRNA Vaccines for Infectious Diseases Market 14.7 PEST Analysis of mRNA Vaccines for Infectious Diseases Market 15 Analysis of the mRNA Vaccines for Infectious Diseases Industry Chain 15.1 Overview of the Industry Chain 15.2 Upstream Segment Analysis 15.3 Midstream Segment Analysis 15.3.1 Manufacturing, Processing or Conversion Process Analysis 15.3.2 Key Technology Analysis 15.4 Downstream Segment Analysis 15.4.1 Downstream Customer List and Contact Details 15.4.2 Customer Concerns or Preference Analysis 16 Conclusion 17 Appendix 17.1 Methodology 17.2 Research Process and Data Source 17.3 Disclaimer 17.4 Note 17.5 Examples of Clients 17.6 DisclaimerResearch Methodology The research methodology employed in this study follows a structured, four-stage process designed to ensure the accuracy, consistency, and relevance of all data and insights presented. The process begins with Information Procurement, wherein data is collected from a wide range of primary and secondary sources. This is followed by Information Analysis, during which the collected data is systematically mapped, discrepancies across sources are examined, and consistency is established through cross-validation.
Subsequently, the Market Formulation phase involves placing verified data points into an appropriate market context to generate meaningful conclusions. This step integrates analyst interpretation and expert heuristics to refine findings and ensure applicability. Finally, all conclusions undergo a rigorous Validation and Publishing process, where each data point is re-evaluated before inclusion in the final deliverable. The methodology emphasizes bidirectional flow and reversibility between key stages to maintain flexibility and reinforce the integrity of the analysis.
Research Process The market research process follows a structured and iterative methodology designed to ensure accuracy, depth, and reliability. It begins with scope definition and research design, where the research objectives are clearly outlined based on client requirements, emerging market trends, and initial exploratory insights. This phase provides strategic direction for all subsequent stages of the research. Data collection is then conducted through both secondary and primary research. Secondary research involves analyzing publicly available and paid sources such as company filings, industry journals, and government databases to build foundational knowledge. This is followed by primary research, which includes direct interviews and surveys with key industry stakeholders—such as manufacturers, distributors, and end users—to gather firsthand insights and address data gaps identified earlier. Techniques included CATI (Computer-Assisted Telephonic Interviewing), CAWI (Computer-Assisted Web Interviewing), CAVI (Computer-Assisted Video Interviewing via platforms like Zoom and WebEx), and CASI (Computer-Assisted Self Interviewing via email or LinkedIn).
